Companies › SynOx Therapeutics
1 active drug program in 1 registered trial: 1 Phase 3; Oncology; next expected readout Sep 2030.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Emactuzumab Macrophage colony stimulating factor receptor inhibitor | CSF1R | Phase 3 | TGCT | Sep 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05417789 | Emactuzumab | Phase 3 | TGCT | Oncology | Sep 2030 |
NingBo Junyan Hongshi Biosciences Taizhou Hanzhong biomedical InSightec NovoCure Summit Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.